Larvol Delta - Postmarketing-safety-signal-profile-of-mavacamten-in-the-FDA-adverse-event-reporting-system-FAERS-a-disproportionality-analysis

Camzyos (mavacamten) - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42780356

Chi Chen; Juan Wu; Tao Zheng

Sep 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next